Primary refractory multiple myeloma: a real-world experience with 85 cases

References

• Mikhael JR, Dingli D, Roy V, Mayo Clinic, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–376.
   PubMed Web of Science ®Google Scholar
• Noll JE, Williams SA, Tong CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163–171.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337–1341.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621–4629.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. JCO. 2010;28(34):5101–5109.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IGH, Van Der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JCO. 2012;30(24):2946–2955.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res. 2016;5:2053. pii:F1000 Faculty Rev-2053.
   Google Scholar
• Cohen YC, Joffe E, Benyamini N, et al. Primary failure of bortezomib in newly diagnosed multiple myeloma-understanding the magnitude, predictors, and significance. Leuk Lymphoma. 2016;57(6):1382–1388.
   PubMed Web of Science ®Google Scholar
• Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355–1361.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Saranga A, Gatt ME, et al. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: an observational multi-center retrospective study. Am J Hematol. 2018;93(6):810–815.
   PubMed Web of Science ®Google Scholar
• Veltri LW, Milton DR, Delgado R, et al. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017;123(18):3568–3575.
   PubMed Web of Science ®Google Scholar
• Majithia N, Vincent Rajkumar S, Lacy MQ, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015; 90(11):981–985.
   PubMed Web of Science ®Google Scholar
• Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(2):335–341.
   PubMed Web of Science ®Google Scholar
• Miller KC, Gertz MA, Buadi FK, et al. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2019;54(12):2039–2050.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Management of induction failures in newly diagnosed transplant-eligible multiple myeloma. Leuk Lymphoma. 2020;61(1):1–3.
   PubMed Web of Science ®Google Scholar
• Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau JL, Miguel JS, International Myeloma Working Group, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. JCO. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Lee SE, Yoon JH, Shin SH, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93(4):627–634.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplantation in multiple myeloma: Impact of response failure with thalidomide or lenalidomide induction. Blood. 2010;115(12):2348–2353.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, International Myeloma Working Group, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277.
   PubMed Web of Science ®Google Scholar
• Zhuang J, Da Y, Li H, et al. Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leuk Res. 2014;38(2):188–193.
   PubMed Web of Science ®Google Scholar
• Kazmi SM, Nusrat M, Gunaydin H, et al. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(11):687–693.
   PubMed Web of Science ®Google Scholar
• Scott EC, Hari P, Sharma M, et al. Post-transplant outcomes in high-risk compared with non–high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transplant. 2016;22(10):1893–1899.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752–5758.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992.
   PubMed Web of Science ®Google Scholar